Johnson & Johnson Reports 2010 Third-Quarter Results:
Sales of $15.0 Billion Decreased 0.7% Versus 2009 Third-Quarter; EPS of $1.23 increased 2.5% Versus 2009 Third-Quarter
NEW BRUNSWICK, N.J., Oct 19, 2010 /PRNewswire via COMTEX News Network/ -- Johnson & Johnson (NYSE: JNJ) today announced sales of $15.0 billion for the third quarter of 2010, a decrease of 0.7% as compared to the third quarter of 2009. Operational results increased 0.1% and the negative impact of currency was 0.8%. Domestic sales declined 2.5%, while international sales increased 1.1%, reflecting operational growth of 2.6% and a negative currency impact of 1.5%.
Net earnings and diluted earnings per share for the third quarter of 2010 were $3.4 billion and $1.23, respectively, representing increases of 2.2% and 2.5%, as compared to the same period in 2009.
The Company raised its earnings guidance for full-year 2010 to $4.70 - $4.80 per share, reflecting recent currency exchange rates. The Company's guidance excludes the impact of special items.
"We continue to deliver solid earnings while investing in our future through complementary strategic partnerships and acquisitions," said William C. Weldon, Chairman and Chief Executive Officer. "Our pharmaceutical business has returned to growth this year and we continue to advance our pipeline with promising clinical data in key therapeutic areas. We are pleased with the strong performance of newly launched products in both our pharmaceutical and medical device and diagnostics businesses."
Worldwide Consumer sales of $3.6 billion for the third quarter represented a decrease of 10.6% versus the prior year consisting of an operational decline of 10.2% and a negative impact from currency of 0.4%. Domestic sales decreased 24.5%; international sales decreased 0.3%, which reflected an operational increase of 0.4% and a negative currency impact of 0.7%.
Positive contributors to operational results were Dabao skin care products, baby care products, and international sales of anti-smoking aids. Sales were significantly impacted by the previously announced recalls of certain over-the-counter medicines and the suspension of manufacturing at the McNeil Consumer Healthcare Fort Washington, Pa., facility as well as the currency devaluation in Venezuela. With respect to the ongoing remediation actions at the Fort Washington facility, Mr. Weldon stated, "We have made considerable progress, and are working diligently to reopen what will be a state of the art facility. Working across our production network, we have begun restoring the supply of some of the impacted children's medicines, which will increase in the coming months."
Worldwide Pharmaceutical sales of $5.5 billion for the third quarter represented an increase of 4.7% versus the prior year with operational growth of 5.9% and a negative impact from currency of 1.2%. Domestic sales increased 6.9%; international sales increased 2.0%, which reflected an operational increase of 4.6% and a negative currency impact of 2.6%.
Several products had strong operational growth including sales of REMICADE(R) (infliximab), a biologic approved for the treatment of a number of immune mediated inflammatory diseases; PREZISTA(R) (darunavir), a treatment for HIV; international sales of RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Treatment, an antipsychotic medication; INTELENCE(R) (etravirine), a next generation non-nucleoside reverse transcriptase inhibitor for HIV; and VELCADE(R) (bortezomib), a treatment for multiple myeloma.
Sales growth also includes the strong performance of newly launched products including STELARA(TM) (ustekinumab), a biologic approved for the treatment of moderate to severe plaque psoriasis; SIMPONI(TM) (golimumab), a biologic approved to treat adults with moderate to severe rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis; and INVEGA(R) SUSTENNA(TM) (paliperidone palmitate), an extended-release injectable suspension for the acute and maintenance treatment of schizophrenia in adults.
During the quarter, the Company submitted new drug applications for TMC 278, a once-daily investigational non-nucleoside reverse transcriptase inhibitor (NNRTI) for the treatment of HIV, to the U.S. Food and Drug Administration and the European Medicines Agency. A supplemental Biologics License Application was also filed in the U.S. to expand the SIMPONI(R) (golimumab) label in rheumatoid arthritis (RA) to include inhibiting the progression of structural damage in the treatment of moderately to severely active RA.
In October, the Company entered into an agreement to acquire all outstanding equity of Crucell N.V. not already owned by the Company for approximately euro 1.75 billion in a cash tender offer. Crucell is a global biopharmaceutical company focused on the research & development, production and marketing of vaccines and antibodies against infectious disease worldwide.
Worldwide Medical Devices and Diagnostics sales of $5.9 billion for the third quarter represented an increase of 1.3% versus the prior year consisting of an operational increase of 1.9% and a negative currency impact of 0.6%. Domestic sales increased 1.2%; international sales increased 1.4%, which reflected an operational increase of 2.6% and a negative currency impact of 1.2%.
Primary contributors to operational growth included Ethicon's surgical care products; Ethicon Endo-Surgery's minimally invasive and advanced sterilization products; Biosense Webster's electrophysiology business; and DePuy's orthopaedic joint reconstruction business. This growth was partially offset by lower sales in the Cordis franchise, reflecting continued competition in the drug-eluting stent market.
During the quarter, the Company completed the acquisition of Micrus Endovascular, a global developer and manufacturer of minimally invasive devices for the treatment of hemorrhagic and ischemic stroke.
About Johnson & Johnson
Caring for the world, one person at a time... inspires and unites the people of Johnson & Johnson. We embrace research and science - bringing innovative ideas, products and services to advance the health and well-being of people. Our approximately 114,000 employees at more than 250 Johnson & Johnson companies work with partners in health care to touch the lives of over a billion people every day, throughout the world.
NOTE TO INVESTORS
Johnson & Johnson will conduct a meeting with financial analysts to discuss this news release today at 8:30 a.m., Eastern Time. A simultaneous webcast of the meeting for investors and other interested parties may be accessed by visiting the Johnson & Johnson website at www.investor.jnj.com. A replay and podcast will be available approximately two hours after the live webcast by visiting www.investor.jnj.com.
Copies of the financial schedules accompanying this press release are available at www.investor.jnj.com/historical-sales.cfm. These schedules include supplementary sales data, a condensed consolidated statement of earnings, and sales of key products/franchises. Additional information on Johnson & Johnson, including a pharmaceutical pipeline of selected compounds in late stage development and medical devices and diagnostics pipeline of selected products, can be found on the Company's website at www.jnj.com
(This press release contains "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements are based on current expectations of future events. If underlying assumptions prove inaccurate or unknown risks or uncertainties materialize, actual results could vary materially from Johnson & Johnson's expectations and projections. Risks and uncertainties include general industry conditions and competition; economic conditions, such as interest rate and currency exchange rate fluctuations; technological advances and patents attained by competitors; challenges inherent in new product development, including obtaining regulatory approvals; domestic and foreign health care reforms and governmental laws and regulations; and trends toward health care cost containment. A further list and description of these risks, uncertainties and other factors can be found in Exhibit 99 of Johnson & Johnson's Annual Report on Form 10-K for the fiscal year ended January 3, 2010. Copies of this Form 10-K, as well as subsequent filings, are available online at www.sec.gov, www.jnj.com or on request from Johnson & Johnson. Johnson & Johnson does not undertake to update any forward-looking statements as a result of new information or future events or developments.)
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited;
Dollars in
Millions) THIRD QUARTER
----------- -------------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to
customers by
segment of
business
Consumer
U.S. $1,277 1,691 (24.5)% (24.5) -
International 2,290 2,298 (0.3) 0.4 (0.7)
------------- ----- ----- ---- --- ----
3,567 3,989 (10.6) (10.2) (0.4)
===== ===== ===== ===== ====
Pharmaceutical
U.S. 3,054 2,857 6.9 6.9 -
International 2,441 2,392 2.0 4.6 (2.6)
------------- ----- ----- --- --- ----
5,495 5,249 4.7 5.9 (1.2)
===== ===== === === ====
Med Devices &
Diagnostics
U.S. 2,800 2,766 1.2 1.2 -
International 3,120 3,077 1.4 2.6 (1.2)
------------- ----- ----- --- --- ----
5,920 5,843 1.3 1.9 (0.6)
===== ===== === === ====
U.S. 7,131 7,314 (2.5) (2.5) -
International 7,851 7,767 1.1 2.6 (1.5)
------------- ----- ----- --- --- ----
Worldwide $14,982 15,081 (0.7)% 0.1 (0.8)
========= ======= ====== ===== === ====
(Unaudited; Dollars in
Millions) NINE MONTHS
---------------------- -----------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers by
segment of business
Consumer
U.S. $4,300 5,125 (16.1)% (16.1) -
International 6,680 6,429 3.9 0.5 3.4
------------- ----- ----- --- --- ---
10,980 11,554 (5.0) (6.9) 1.9
====== ====== ==== ==== ===
Pharmaceutical
U.S. 9,370 9,703 (3.4) (3.4) -
International 7,316 6,824 7.2 5.3 1.9
------------- ----- ----- --- --- ---
16,686 16,527 1.0 0.2 0.8
====== ====== === === ===
Med Devices &
Diagnostics
U.S. 8,551 8,194 4.4 4.4 -
International 9,726 9,071 7.2 4.5 2.7
------------- ----- ----- --- --- ---
18,277 17,265 5.9 4.5 1.4
====== ====== === === ===
U.S. 22,221 23,022 (3.5) (3.5) -
International 23,722 22,324 6.3 3.7 2.6
------------- ------ ------ --- --- ---
Worldwide $45,943 45,346 1.3% 0.0 1.3
========= ======= ====== === === ===
Johnson & Johnson and Subsidiaries
----------------------------------
Supplementary Sales Data
(Unaudited;
Dollars in
Millions) THIRD QUARTER
-------------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to
customers by
geographic area
U.S. $7,131 7,314 (2.5)% (2.5) -
---- ------ ----- ----- ---- ---
Europe 3,629 3,879 (6.4) 1.8 (8.2)
Western
Hemisphere
excluding U.S. 1,424 1,338 6.4 1.7 4.7
Asia-Pacific,
Africa 2,798 2,550 9.7 4.1 5.6
International 7,851 7,767 1.1 2.6 (1.5)
------------- ----- ----- --- --- ----
Worldwide $14,982 15,081 (0.7)% 0.1 (0.8)
========= ======= ====== ===== === ====
(Unaudited; Dollars
in Millions) NINE MONTHS
-----------
Percent Change
--------------
2010 2009 Total Operations Currency
---- ---- ----- ---------- --------
Sales to customers
by geographic area
U.S. $22,221 23,022 (3.5)% (3.5) -
---- ------- ------ ----- ---- ---
Europe 11,563 11,522 0.4 2.6 (2.2)
Western Hemisphere
excluding U.S. 4,079 3,615 12.8 2.5 10.3
Asia-Pacific,
Africa 8,080 7,187 12.4 5.9 6.5
International 23,722 22,324 6.3 3.7 2.6
------------- ------ ------ --- --- ---
Worldwide $45,943 45,346 1.3% 0.0 1.3
========= ======= ====== === === ===
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in
Millions Except
Per Share
Figures) THIRD QUARTER
---------------- -------------
2010 2009 Percent
---- ----
Percent Percent Increase
to to
Amount Sales Amount Sales (Decrease)
------ ------ ------ ------ ----------
Sales to
customers $14,982 100.0 $15,081 100.0 (0.7)
---------- ------- ----- ------- ----- ----
Cost of products
sold 4,594 30.7 4,434 29.4 3.6
Selling,
marketing and
administrative
expenses 4,709 31.4 4,767 31.6 (1.2)
Research expense 1,657 11.1 1,617 10.7 2.5
Interest
(income)expense,
net 95 0.6 114 0.7
Other
(income)expense,
net (292) (2.0) (96) (0.6)
----------------- ---- ---- --- ----
Earnings before
provision for
taxes on income 4,219 28.2 4,245 28.2 (0.6)
Provision for
taxes on income 802 5.4 900 6.0 (10.9)
---------------- --- --- --- --- -----
Net earnings $3,417 22.8 $3,345 22.2 2.2
============ ====== ==== ====== ==== ===
Net earnings per
share
(Diluted) $1.23 $1.20 2.5
Average shares
outstanding
(Diluted) 2,786.4 2,793.0
Effective tax
rate 19.0% 21.2%
Johnson & Johnson and Subsidiaries
----------------------------------
Condensed Consolidated Statement of Earnings
(Unaudited; in Millions Except Per Share
Figures) NINE MONTHS
---------------------------------------- -----------
2010
----
Percent
Amount to Sales
------ --------
Sales to customers $45,943 100.0
------------------ ------- -----
Cost of products sold 13,752 29.9
Selling, marketing and administrative
expenses 14,244 31.0
Research expense 4,862 10.6
Interest (income)expense, net 234 0.5
Other (income)expense, net (1,868) (4.0)
-------------------------- ------ ----
Earnings before provision for taxes on
income 14,719 32.0
Provision for taxes on income 3,327 7.2
----------------------------- ----- ---
Net earnings $11,392 24.8
============ ======= ====
Net earnings per share (Diluted) $4.08
Average shares outstanding (Diluted) 2,792.0
Effective tax rate 22.6%
Adjusted earnings before provision for
taxes and net earnings
Earnings before provision for taxes on
income $13,379 (1) 29.1
Net earnings $10,415 (1) 22.7
Net earnings per share (Diluted) $3.73 (1)
Effective tax rate 22.2%
------------------ ----
(Unaudited; in Millions Except
Per Share Figures) NINE MONTHS
------------------------------ -----------
2009 Percent
----
Percent Increase
Amount to Sales (Decrease)
------ -------- ----------
Sales to customers $45,346 100.0 1.3
------------------ ------- ----- ---
Cost of products sold 13,135 29.0 4.7
Selling, marketing and
administrative expenses 14,172 31.3 0.5
Research expense 4,773 10.5 1.9
Interest (income)expense, net 280 0.6
Other (income)expense, net (165) (0.4)
-------------------------- ---- ----
Earnings before provision for
taxes on income 13,151 29.0 11.9
Provision for taxes on income 3,091 6.8 7.6
----------------------------- ----- --- ---
Net earnings $10,060 22.2 13.2
============ ======= ==== ====
Net earnings per share (Diluted) $3.61 13.0
Average shares outstanding
(Diluted) 2,787.9
Effective tax rate 23.5%
Adjusted earnings before
provision for taxes and net
earnings
Earnings before provision for
taxes on income $13,151 29.0 1.7
Net earnings $10,060 22.2 3.5
Net earnings per share (Diluted) $3.61 3.3
Effective tax rate 23.5%
------------------ ----
REPORTED SALES vs. PRIOR PERIOD ($MM)
-------------------------------------
THIRD QUARTER
-------------
% Change
--------
Operational
2010 2009 Reported (1) Currency
---- ---- -------- -------------- --------
CONSUMER
SEGMENT (2)
------------
SKIN CARE
---------
US 311 370 -15.9% -15.9% -
Intl 489 472 3.6% 3.7% -0.1%
WW 800 842 -5.0% -4.9% -0.1%
BABY CARE
---------
US 104 102 2.0% 2.0% -
Intl 462 442 4.5% 3.6% 0.9%
WW 566 544 4.0% 3.3% 0.7%
ORAL CARE
---------
US 164 187 -12.3% -12.3% -
Intl 220 223 -1.3% -2.2% 0.9%
WW 384 410 -6.3% -6.8% 0.5%
OTC/
NUTRITIONALS
-------------
US 438 732 -40.2% -40.2% -
Intl 671 666 0.8% 3.5% -2.7%
WW 1,109 1,398 -20.7% -19.4% -1.3%
WOMEN'S HEALTH
--------------
US 121 142 -14.8% -14.8% -
Intl 338 360 -6.1% -5.1% -1.0%
WW 459 502 -8.6% -7.9% -0.7%
WOUND CARE/
OTHER
-----------
US 139 158 -12.0% -12.0% -
Intl 110 135 -18.5% -18.5% 0.0%
WW 249 293 -15.0% -15.0% 0.0%
TOTAL CONSUMER
--------------
US 1,277 1,691 -24.5% -24.5% -
Intl 2,290 2,298 -0.3% 0.4% -0.7%
WW 3,567 3,989 -10.6% -10.2% -0.4%
See footnotes
on last page
PHARMACEUTICAL
SEGMENT (2)
(6)
------------------
ACIPHEX/PARIET
--------------
US 116 131 -11.5% -11.5% -
Intl 124 130 -4.6% 0.8% -5.4%
WW 240 261 -8.0% -5.3% -2.7%
CONCERTA
--------
US 214 205 4.4% 4.4% -
Intl 85 79 7.6% 9.3% -1.7%
WW 299 284 5.3% 5.8% -0.5%
DURAGESIC/
FENTANYL
TRANSDERMAL
------------
US 42 38 10.5% 10.5% -
Intl 142 168 -15.5% -14.2% -1.3%
WW 184 206 -10.7% -9.6% -1.1%
LEVAQUIN/
FLOXIN
---------
US 274 294 -6.8% -6.8% -
Intl 12 17 -29.4% -31.5% 2.1%
WW 286 311 -8.0% -8.1% 0.1%
PREZISTA
--------
US 102 78 30.8% 30.8% -
Intl 128 73 75.3% 82.7% -7.4%
WW 230 151 52.3% 55.9% -3.6%
PROCRIT/EPREX
-------------
US 204 299 -31.8% -31.8% -
Intl 202 243 -16.9% -11.9% -5.0%
WW 406 542 -25.1% -22.9% -2.2%
REMICADE
--------
US 857 822 4.3% 4.3% -
US Exports (3) 365 208 75.5% 75.5% -
Intl 7 6 16.7% 16.7% -
WW 1,229 1,036 18.6% 18.6% -
RISPERDAL/
RISPERIDONE
------------
US (2) 35 -105.7% -105.7% -
Intl 123 157 -21.7% -22.8% 1.1%
WW 121 192 -37.0% -37.9% 0.9%
RISPERDAL
CONSTA
---------
US 108 129 -16.3% -16.3% -
Intl 270 224 20.5% 26.6% -6.1%
WW 378 353 7.1% 11.0% -3.9%
TOPAMAX
-------
US 46 72 -36.1% -36.1% -
Intl 81 103 -21.4% -18.1% -3.3%
WW 127 175 -27.4% -25.4% -2.0%
VELCADE
-------
US - - - - -
Intl 246 231 6.5% 10.1% -3.6%
WW 246 231 6.5% 10.1% -3.6%
OTHER
-----
US 728 546 33.3% 33.3% -
Intl 1,021 961 6.2% 7.4% -1.2%
WW 1,749 1,507 16.1% 16.9% -0.8%
TOTAL
PHARMACEUTICAL
---------------
US 3,054 2,857 6.9% 6.9% -
Intl 2,441 2,392 2.0% 4.6% -2.6%
WW 5,495 5,249 4.7% 5.9% -1.2%
--- --- --- --- ----
MAJOR NEW
PHARM
PRODUCTS (4)
-------------
INVEGA
------
US 63 61 3.3% 3.3% -
Intl 35 36 -2.8% 1.7% -4.5%
WW 98 97 1.0% 2.7% -1.7%
See footnotes
on last page
MEDICAL
DEVICES AND
DIAGNOSTICS
(2)
------------
CORDIS (5)
---------
US 246 233 5.6% 5.6% -
Intl 350 407 -14.0% -13.5% -0.5%
WW 596 640 -6.9% -6.6% -0.3%
DEPUY
-----
US 748 740 1.1% 1.1% -
Intl 561 544 3.1% 4.8% -1.7%
WW 1,309 1,284 1.9% 2.6% -0.7%
DIABETES CARE
-------------
US 338 332 1.8% 1.8% -
Intl 275 302 -8.9% 0.2% -9.1%
WW 613 634 -3.3% 1.0% -4.3%
ETHICON
-------
US 480 439 9.3% 9.3% -
Intl 592 580 2.1% 3.4% -1.3%
WW 1,072 1,019 5.2% 6.0% -0.8%
ETHICON ENDO-
SURGERY
-------------
US 484 499 -3.0% -3.0% -
Intl 653 607 7.6% 8.4% -0.8%
WW 1,137 1,106 2.8% 3.3% -0.5%
ORTHO-
CLINICAL
DIAGNOSTICS
------------
US 263 285 -7.7% -7.7% -
Intl 235 216 8.8% 9.2% -0.4%
WW 498 501 -0.6% -0.4% -0.2%
VISION CARE
-----------
US 241 238 1.3% 1.3% -
Intl 454 421 7.8% 4.0% 3.8%
WW 695 659 5.5% 3.1% 2.4%
TOTAL MEDICAL
DEVICES AND
DIAGNOSTICS
-------------
US 2,800 2,766 1.2% 1.2% -
Intl 3,120 3,077 1.4% 2.6% -1.2%
WW 5,920 5,843 1.3% 1.9% -0.6%
REPORTED SALES vs. PRIOR PERIOD ($MM)
-------------------------------------
NINE MONTHS
-----------
% Change
--------
Operational
2010 2009 Reported (1) Currency
---- ---- -------- -------------- --------
CONSUMER
SEGMENT (2)
------------
SKIN CARE
---------
US 1,185 1,204 -1.6% -1.6% -
Intl 1,378 1,313 5.0% 2.0% 3.0%
WW 2,563 2,517 1.8% 0.2% 1.6%
BABY CARE
---------
US 306 308 -0.6% -0.6% -
Intl 1,326 1,233 7.5% 3.3% 4.2%
WW 1,632 1,541 5.9% 2.5% 3.4%
ORAL CARE
---------
US 486 549 -11.5% -11.5% -
Intl 651 612 6.4% 1.3% 5.1%
WW 1,137 1,161 -2.1% -4.8% 2.7%
OTC/
NUTRITIONALS
-------------
US 1,472 2,137 -31.1% -31.1% -
Intl 1,985 1,919 3.4% 0.7% 2.7%
WW 3,457 4,056 -14.8% -16.1% 1.3%
WOMEN'S
HEALTH
-------
US 404 443 -8.8% -8.8% -
Intl 990 963 2.8% -0.4% 3.2%
WW 1,394 1,406 -0.9% -3.1% 2.2%
WOUND CARE/
OTHER
-----------
US 447 484 -7.6% -7.6% -
Intl 350 389 -10.0% -13.9% 3.9%
WW 797 873 -8.7% -10.4% 1.7%
TOTAL
CONSUMER
---------
US 4,300 5,125 -16.1% -16.1% -
Intl 6,680 6,429 3.9% 0.5% 3.4%
WW 10,980 11,554 -5.0% -6.9% 1.9%
See footnotes
on last page
PHARMACEUTICAL
SEGMENT (2)
(6)
-------------------
ACIPHEX/
PARIET
--------
US 356 397 -10.3% -10.3% -
Intl 398 387 2.8% 2.0% 0.8%
WW 754 784 -3.8% -4.2% 0.4%
CONCERTA
--------
US 668 707 -5.5% -5.5% -
Intl 283 238 18.9% 14.3% 4.6%
WW 951 945 0.6% -0.6% 1.2%
DURAGESIC/
FENTANYL
TRANSDERMAL
------------
US 117 163 -28.2% -28.2% -
Intl 435 492 -11.6% -13.4% 1.8%
WW 552 655 -15.7% -17.1% 1.4%
LEVAQUIN/
FLOXIN
---------
US 926 1,045 -11.4% -11.4% -
Intl 31 53 -41.5% -44.2% 2.7%
WW 957 1,098 -12.8% -12.9% 0.1%
PREZISTA
--------
US 290 215 34.9% 34.9% -
Intl 331 198 67.2% 66.8% 0.4%
WW 621 413 50.4% 50.2% 0.2%
PROCRIT/EPREX
-------------
US 800 950 -15.8% -15.8% -
Intl 655 719 -8.9% -9.2% 0.3%
WW 1,455 1,669 -12.8% -12.9% 0.1%
REMICADE
--------
US 2,420 2,330 3.9% 3.9% -
US Exports
(3) 1,106 821 34.7% 34.7% -
Intl 19 15 26.7% 26.7% 0.0%
WW 3,545 3,166 12.0% 12.0% -
RISPERDAL/
RISPERIDONE
------------
US (14) 223 -106.3% -106.3% -
Intl 390 483 -19.3% -21.7% 2.4%
WW 376 706 -46.7% -48.4% 1.7%
RISPERDAL
CONSTA
---------
US 340 386 -11.9% -11.9% -
Intl 772 640 20.6% 20.3% 0.3%
WW 1,112 1,026 8.4% 8.2% 0.2%
TOPAMAX
-------
US 162 642 -74.8% -74.8% -
Intl 255 317 -19.6% -20.5% 0.9%
WW 417 959 -56.5% -56.8% 0.3%
VELCADE
-------
US - - 0.0% 0.0% -
Intl 793 652 21.6% 20.3% 1.3%
WW 793 652 21.6% 20.3% 1.3%
OTHER
-----
US 2,199 1,824 20.6% 20.6% -
Intl 2,954 2,630 12.3% 9.4% 2.9%
WW 5,153 4,454 15.7% 14.0% 1.7%
TOTAL
PHARMACEUTICAL
---------------
US 9,370 9,703 -3.4% -3.4% -
Intl 7,316 6,824 7.2% 5.3% 1.9%
WW 16,686 16,527 1.0% 0.2% 0.8%
---- ---- --- --- ---
MAJOR NEW
PHARM
PRODUCTS (4)
-------------
INVEGA
------
US 200 194 3.1% 3.1% -
Intl 108 93 16.1% 15.2% 0.9%
WW 308 287 7.3% 7.0% 0.3%
See footnotes
on last page
MEDICAL
DEVICES AND
DIAGNOSTICS
(2)
------------
CORDIS (5)
---------
US 762 731 4.2% 4.2% -
Intl 1,161 1,251 -7.2% -9.4% 2.2%
WW 1,923 1,982 -3.0% -4.4% 1.4%
DEPUY
-----
US 2,338 2,268 3.1% 3.1% -
Intl 1,800 1,631 10.4% 7.3% 3.1%
WW 4,138 3,899 6.1% 4.8% 1.3%
DIABETES CARE
-------------
US 941 908 3.6% 3.6% -
Intl 885 877 0.9% 2.1% -1.2%
WW 1,826 1,785 2.3% 2.9% -0.6%
ETHICON
-------
US 1,499 1,296 15.7% 15.7% -
Intl 1,852 1,717 7.9% 5.3% 2.6%
WW 3,351 3,013 11.2% 9.7% 1.5%
ETHICON ENDO-
SURGERY
-------------
US 1,474 1,442 2.2% 2.2% -
Intl 2,027 1,794 13.0% 9.9% 3.1%
WW 3,501 3,236 8.2% 6.5% 1.7%
ORTHO-
CLINICAL
DIAGNOSTICS
------------
US 815 846 -3.7% -3.7% -
Intl 702 616 14.0% 11.1% 2.9%
WW 1,517 1,462 3.8% 2.6% 1.2%
VISION CARE
-----------
US 722 703 2.7% 2.7% -
Intl 1,299 1,185 9.6% 4.9% 4.7%
WW 2,021 1,888 7.0% 4.0% 3.0%
TOTAL MEDICAL
DEVICES AND
DIAGNOSTICS
-------------
US 8,551 8,194 4.4% 4.4% -
Intl 9,726 9,071 7.2% 4.5% 2.7%
WW 18,277 17,265 5.9% 4.5% 1.4%
(1) Operational growth excludes the effect of currency
(2) Select areas (unaudited)
(3) Reported in U.S. sales
(4) Included in Other
(5) Includes sales of Drug-Eluting Stents for Q3 2010 of $47, $89
and $136MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for Q3 2009 of $53, $158 and
$211MM Domestic, International and Worldwide respectively
Includes sales of Drug-Eluting Stents for September YTD 2010 of
$166, $327 and $493MM Domestic, International and Worldwide
respectively
Includes sales of Drug-Eluting Stents for September YTD 2009 of
$189, $507 and $696MM Domestic, International and Worldwide
respectively
(6) Conforms to current presentation